CY1124273T1 - Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη - Google Patents
Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινηInfo
- Publication number
- CY1124273T1 CY1124273T1 CY20211100585T CY211100585T CY1124273T1 CY 1124273 T1 CY1124273 T1 CY 1124273T1 CY 20211100585 T CY20211100585 T CY 20211100585T CY 211100585 T CY211100585 T CY 211100585T CY 1124273 T1 CY1124273 T1 CY 1124273T1
- Authority
- CY
- Cyprus
- Prior art keywords
- gemcitabine
- pancreatic cancer
- cancer treatments
- treatments including
- including paclitaxel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751820P | 2013-01-11 | 2013-01-11 | |
| US201361752355P | 2013-01-14 | 2013-01-14 | |
| US13/794,480 US9511046B2 (en) | 2013-01-11 | 2013-03-11 | Methods of treating pancreatic cancer |
| PCT/US2014/011145 WO2014110443A1 (en) | 2013-01-11 | 2014-01-10 | Methods of treating pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124273T1 true CY1124273T1 (el) | 2022-11-25 |
Family
ID=51165317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100585T CY1124273T1 (el) | 2013-01-11 | 2021-06-30 | Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US9511046B2 (enExample) |
| EP (1) | EP2943192B9 (enExample) |
| JP (3) | JP6342918B2 (enExample) |
| KR (1) | KR102205710B1 (enExample) |
| CN (2) | CN109793728A (enExample) |
| AU (1) | AU2013203699B2 (enExample) |
| BR (1) | BR112015016681A8 (enExample) |
| CA (1) | CA2897589C (enExample) |
| CY (1) | CY1124273T1 (enExample) |
| DK (1) | DK2943192T3 (enExample) |
| ES (1) | ES2878145T3 (enExample) |
| HK (1) | HK1216853A1 (enExample) |
| HR (1) | HRP20211062T1 (enExample) |
| HU (1) | HUE056612T2 (enExample) |
| IL (2) | IL239739A0 (enExample) |
| LT (1) | LT2943192T (enExample) |
| MX (1) | MX382017B (enExample) |
| NZ (2) | NZ734971A (enExample) |
| PL (1) | PL2943192T3 (enExample) |
| PT (1) | PT2943192T (enExample) |
| RS (1) | RS62076B1 (enExample) |
| SI (1) | SI2943192T1 (enExample) |
| SM (1) | SMT202100377T1 (enExample) |
| WO (1) | WO2014110443A1 (enExample) |
| ZA (1) | ZA201504877B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| ES2678448T3 (es) | 2005-02-18 | 2018-08-10 | Abraxis Bioscience, Llc | Combinaciones y modos de administración de agentes terapéuticos y terapia combinada |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| TWI417114B (zh) | 2005-08-31 | 2013-12-01 | Abraxis Bioscience Llc | 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 |
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| DK2155188T3 (da) * | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| ES2580135T3 (es) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| NZ628423A (en) | 2010-03-29 | 2016-03-31 | Abraxis Bioscience Llc | Methods of treating cancer |
| AU2011232862B2 (en) | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| RU2576609C2 (ru) | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
| KR101850566B1 (ko) * | 2010-06-07 | 2018-04-19 | 아브락시스 바이오사이언스, 엘엘씨 | 증식성 질환의 치료를 위한 조합 치료 방법 |
| CA3063641A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| DK2790675T3 (da) | 2011-12-14 | 2019-09-09 | Abraxis Bioscience Llc | Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| NZ630392A (en) | 2013-03-12 | 2016-10-28 | Abraxis Bioscience Llc | Methods of treating lung cancer |
| RU2015143490A (ru) | 2013-03-14 | 2017-04-26 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| CA3026452C (en) | 2015-06-04 | 2023-03-21 | Crititech, Inc. | Nozzle assembly and methods for use |
| HUE070408T2 (hu) | 2015-06-29 | 2025-06-28 | Abraxis Bioscience Llc | Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra |
| US10925852B2 (en) * | 2015-06-30 | 2021-02-23 | The Trustees Of Columbia University In The City Of New York | Talc-bound compositions and uses thereof |
| CA3018989A1 (en) | 2016-04-04 | 2017-10-12 | Crititech, Inc. | Methods for solid tumor treatment |
| EP3595717A1 (en) * | 2017-03-17 | 2020-01-22 | Imclone, LLC | Combination therapy for pancreatic cancer |
| SG11201909840TA (en) | 2017-06-09 | 2019-11-28 | Crititech Inc | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
| KR20210118468A (ko) | 2017-06-14 | 2021-09-30 | 크리티테크, 인크. | 폐 장애의 치료 방법 |
| RU2020110399A (ru) | 2017-10-03 | 2021-11-09 | Крититек, Инк. | Местная доставка противоопухолевых частиц в комбинации с системной доставкой иммунотерапевтических агентов для лечения рака |
| WO2019183146A1 (en) | 2018-03-20 | 2019-09-26 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| GB201908352D0 (en) * | 2019-06-11 | 2019-07-24 | Innovation Ulster Ltd | Sonodynamic therapy |
| CA3149324A1 (en) * | 2019-08-01 | 2021-02-04 | New York University | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
| JP2022553426A (ja) | 2019-10-28 | 2022-12-22 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| EP4100035A1 (en) * | 2020-02-04 | 2022-12-14 | Swedish Orphan Biovitrum AB (publ) | Pdac treatment regimen |
| WO2024186320A1 (en) * | 2023-03-09 | 2024-09-12 | Minneamrita Therapeutics Llc | Drug combination for treatment of pancreatic cancer |
| CN117099681B (zh) * | 2023-08-28 | 2024-07-05 | 南京农业大学 | 一种利用紫杉醇加倍玉米单倍体的方法 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| WO1994018954A1 (en) | 1993-02-22 | 1994-09-01 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of biologics and compositions useful therefor |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| PT1023050E (pt) | 1997-06-27 | 2013-12-04 | Abraxis Bioscience Llc | Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização |
| AU777528B2 (en) | 1999-04-22 | 2004-10-21 | Abraxis Bioscience, Llc | Long term administration of pharmacologically active agents |
| WO2000071079A2 (en) | 1999-05-21 | 2000-11-30 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| ITMI20020681A1 (it) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| MXPA05006169A (es) | 2002-12-09 | 2006-03-30 | American Biosciences | Composiciones y metodos para el suministro de agentes farmacologicos. |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| AU2012201568B2 (en) | 2005-02-18 | 2014-07-31 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| ES2678448T3 (es) | 2005-02-18 | 2018-08-10 | Abraxis Bioscience, Llc | Combinaciones y modos de administración de agentes terapéuticos y terapia combinada |
| KR20080000682A (ko) * | 2005-04-29 | 2008-01-02 | 코산 바이오사이언시즈, 인코포레이티드 | 17-ａａｇ 또는 17-ａｇ, 또는 이들의 프로드럭을 사용한다발성 골수종의 치료 방법 |
| TWI417114B (zh) | 2005-08-31 | 2013-12-01 | Abraxis Bioscience Llc | 具有增強穩定性之弱水溶性藥物之組合物及其製備方法 |
| JP5368093B2 (ja) | 2005-08-31 | 2013-12-18 | アブラクシス バイオサイエンス， エルエルシー | 増大した安定性を有する難水溶性薬剤の組成物および調製の方法 |
| JP2007297339A (ja) * | 2006-04-29 | 2007-11-15 | Torii Yakuhin Kk | 癌を治療又は検査するための医薬 |
| CA2662140A1 (en) | 2006-08-31 | 2008-03-06 | Abraxis Bioscience, Llc | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| CA2672618C (en) | 2006-12-14 | 2021-03-02 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| KR20090118999A (ko) | 2007-03-07 | 2009-11-18 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
| EP3326630A3 (en) | 2007-05-03 | 2018-08-29 | Abraxis BioScience, LLC | Methods and compositions for treating pulmonary hypertension |
| DK2155188T3 (da) | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| JP2011517683A (ja) | 2008-04-10 | 2011-06-16 | アブラクシス バイオサイエンス， エルエルシー | 疎水性タキサン誘導体の組成物およびその使用 |
| CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| BRPI0906903B8 (pt) * | 2008-04-11 | 2021-05-25 | Seattle Genetics Inc | anticorpo monoclonal e método de detecção da expressão de cd70 |
| BRPI0922823A2 (pt) | 2008-12-11 | 2015-08-18 | Abraxis Bioscience Llc | Combinações e modos de administração de agentes terapêuticos e terapia de combinação |
| GB0900555D0 (en) | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| AU2010224012B2 (en) | 2009-03-13 | 2016-04-28 | Abraxis Bioscience, Llc | Combination therapy with thiocolchicine derivatives |
| CA2758200A1 (en) | 2009-04-10 | 2010-10-14 | Abraxis Bioscience, Llc | Nanoparticle formulations and uses thereof |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| ES2533343T3 (es) * | 2009-05-28 | 2015-04-09 | Abraxis Bioscience, Llc | Uso de 2 anticuerpos anti-SPARC para predecir la respuesta a quimioterapia |
| NZ598588A (en) | 2009-08-25 | 2014-05-30 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| JP2011079788A (ja) * | 2009-10-08 | 2011-04-21 | Oita Univ | 膵癌に対する選択的膵動脈制癌剤注入療法と全身化学療法との併用療法、およびそれに使用する膵癌治療薬 |
| AU2011204405B2 (en) * | 2010-01-05 | 2015-06-18 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
| ES2580135T3 (es) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| AU2011232862B2 (en) | 2010-03-29 | 2016-03-03 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| NZ628423A (en) | 2010-03-29 | 2016-03-31 | Abraxis Bioscience Llc | Methods of treating cancer |
| US20130005678A1 (en) | 2010-03-30 | 2013-01-03 | Clavis Pharma Asa | Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate |
| MY188911A (en) | 2010-06-02 | 2022-01-13 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| RU2576609C2 (ru) | 2010-06-04 | 2016-03-10 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечение рака поджелудочной железы |
| KR101850566B1 (ko) | 2010-06-07 | 2018-04-19 | 아브락시스 바이오사이언스, 엘엘씨 | 증식성 질환의 치료를 위한 조합 치료 방법 |
| CA3063641A1 (en) | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| DK2790675T3 (da) | 2011-12-14 | 2019-09-09 | Abraxis Bioscience Llc | Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CN109200031A (zh) | 2013-02-11 | 2019-01-15 | 阿布拉科斯生物科学有限公司 | 治疗黑素瘤的方法 |
| NZ630392A (en) | 2013-03-12 | 2016-10-28 | Abraxis Bioscience Llc | Methods of treating lung cancer |
| NZ630367A (en) | 2013-03-13 | 2017-02-24 | Abraxis Bioscience Llc | Methods of treatment of pediatric solid tumor |
| RU2015143490A (ru) | 2013-03-14 | 2017-04-26 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения рака мочевого пузыря |
| WO2015157120A1 (en) | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| WO2016141365A1 (en) | 2015-03-05 | 2016-09-09 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
| EP3313381A4 (en) | 2015-06-29 | 2019-02-27 | Abraxis BioScience, LLC | BIOMARKERS FOR NANOPARTICLE COMPOSITIONS |
| HK1247093A1 (zh) | 2015-06-29 | 2018-09-21 | 阿布拉科斯生物科学有限公司 | 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法 |
| HUE070408T2 (hu) | 2015-06-29 | 2025-06-28 | Abraxis Bioscience Llc | Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra |
| US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
-
2013
- 2013-03-11 US US13/794,480 patent/US9511046B2/en active Active
- 2013-04-11 AU AU2013203699A patent/AU2013203699B2/en active Active
-
2014
- 2014-01-10 BR BR112015016681A patent/BR112015016681A8/pt not_active Application Discontinuation
- 2014-01-10 JP JP2015552834A patent/JP6342918B2/ja active Active
- 2014-01-10 KR KR1020157021320A patent/KR102205710B1/ko active Active
- 2014-01-10 SM SM20210377T patent/SMT202100377T1/it unknown
- 2014-01-10 SI SI201431853T patent/SI2943192T1/sl unknown
- 2014-01-10 HR HRP20211062TT patent/HRP20211062T1/hr unknown
- 2014-01-10 CN CN201910067315.0A patent/CN109793728A/zh active Pending
- 2014-01-10 RS RS20210823A patent/RS62076B1/sr unknown
- 2014-01-10 EP EP14737791.5A patent/EP2943192B9/en not_active Revoked
- 2014-01-10 WO PCT/US2014/011145 patent/WO2014110443A1/en not_active Ceased
- 2014-01-10 MX MX2015008898A patent/MX382017B/es unknown
- 2014-01-10 LT LTEP14737791.5T patent/LT2943192T/lt unknown
- 2014-01-10 NZ NZ734971A patent/NZ734971A/en unknown
- 2014-01-10 CA CA2897589A patent/CA2897589C/en active Active
- 2014-01-10 NZ NZ630230A patent/NZ630230A/en unknown
- 2014-01-10 PL PL14737791T patent/PL2943192T3/pl unknown
- 2014-01-10 CN CN201480013217.4A patent/CN105025893A/zh active Pending
- 2014-01-10 PT PT147377915T patent/PT2943192T/pt unknown
- 2014-01-10 HK HK16104890.5A patent/HK1216853A1/zh unknown
- 2014-01-10 HU HUE14737791A patent/HUE056612T2/hu unknown
- 2014-01-10 ES ES14737791T patent/ES2878145T3/es active Active
- 2014-01-10 DK DK14737791.5T patent/DK2943192T3/da active
-
2015
- 2015-07-01 IL IL239739A patent/IL239739A0/en unknown
- 2015-07-07 ZA ZA2015/04877A patent/ZA201504877B/en unknown
-
2016
- 2016-10-06 US US15/287,613 patent/US9855220B2/en active Active
-
2017
- 2017-11-21 US US15/820,022 patent/US10328031B2/en active Active
-
2018
- 2018-02-21 JP JP2018028611A patent/JP6697017B2/ja active Active
-
2019
- 2019-02-27 JP JP2019033910A patent/JP2019081790A/ja active Pending
-
2020
- 2020-02-26 IL IL272905A patent/IL272905A/en unknown
-
2021
- 2021-06-30 CY CY20211100585T patent/CY1124273T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124273T1 (el) | Μεθοδοι αγωγης καρκινου στο παγκρεας που περιλαμβανουν πακλιταξελη και γεμσιταβινη | |
| CY1122721T1 (el) | Αντισωματα που δεσμευουν αχl | |
| CY1124926T1 (el) | Νανοσωματιδια που περιλαμβανουν σιρολιμους και μια αλβουμινη για χρηση στη θεραπεια ογκων απο επιθηλιοειδη κυτταρα | |
| MX389667B (es) | Antagonistas de unión al eje pd-1 y taxanos para usarse en el tratamiento de cáncer. | |
| CY1121907T1 (el) | Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| MX2015010312A (es) | Metodos para tratamiento del melanoma. | |
| MX2015008888A (es) | Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. | |
| CL2015003280A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
| MX374785B (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| MX369863B (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| MX2016015363A (es) | Terapias de combinacion para el tratamiento de cancer. | |
| NI201200175A (es) | Métodos de tratamiento de cáncer de vejiga | |
| CY1122813T1 (el) | Διαλυτος cd33 για την αγωγη μυελοδυσπλαστικων συνδρομων (μds) | |
| UY36075A (es) | Derivados de tubulisina | |
| MX2016004441A (es) | Tratamiento del cancer con una combinacion de plinabulina y taxano. | |
| CY1121821T1 (el) | Θεραπεια συνδυασμου για την αγωγη του καρκινου των ωοθηκων | |
| CY1123019T1 (el) | Σπειροκυκλικες ενωσεις | |
| MX2018003301A (es) | Inhibidores de pcna. | |
| BR112019001398A2 (pt) | métodos para tratamento de câncer de próstata | |
| CY1122998T1 (el) | Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη | |
| ECSP14011792A (es) | Inhibidores de iap | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| CY1122403T1 (el) | Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης |